Newsroom
23 press releases and 54 media coverage stories
Phacilitate: Navigating the Nuances of Process and Analytical Development for Decentralized Production
Phacilitate
Decentralized manufacturing models, where therapies are produced closer to the patient show promise. But the path from research to this decentralized model, while maintaining rigorous Good Manufacturing Practice (GMP) compliance, is anything but easy. In a recent panel discussion, Josh Ludwig shed light on this complex transition.
Read the article : Phacilitate: Navigating the Nuances of Process and Analytical Development for Decentralized ProductionShare: Phacilitate: Navigating the Nuances of Process and Analytical Development for Decentralized Production
The Medicine Maker: The Future of Cell and Gene Therapy Innovation
The Medicine Maker
While cell and gene therapy represent a captivating frontier, ongoing innovation and adaptation to Industry 4.0 principles are essential for progress. In this feature, experts, including Josh Ludwig, Global Director of ScaleReady, delve into the definitions of Industry 4.0 and its implications for the present and future of cell and gene therapy manufacturing.
Read the article : The Medicine Maker: The Future of Cell and Gene Therapy InnovationShare: The Medicine Maker: The Future of Cell and Gene Therapy Innovation
Pharma Manufacturing: 2024 Pharma Predictions
Pharma Manufacturing
The upcoming year promises significant changes driven by historic successes and economic challenges in 2023. Notable events mark the industry's current juncture of innovation and adjustment. Industry leaders, including ScaleReady's Josh Ludwig, predict trends for 2024, including the transformative impact of AI in drug development and key regulatory changes to monitor.
Read the article : Pharma Manufacturing: 2024 Pharma PredictionsShare: Pharma Manufacturing: 2024 Pharma Predictions
Drug Discovery World: Josh Ludwig Discusses Industry Trends and Predictions for 2024
Drug Discovery World
In this issue of Drug Discovery World, Megan Thomas spoke with industry experts about the opportunities and challenges that lie ahead in 2024. Josh Ludwig, Global Director, Commercial Operations at…
Read the article : Drug Discovery World: Josh Ludwig Discusses Industry Trends and Predictions for 2024Share: Drug Discovery World: Josh Ludwig Discusses Industry Trends and Predictions for 2024
Drug Discovery World: Challenges Facing Advanced Therapies
Drug Discovery World
During Advanced Therapies Week (ATW) 2024, Drug Discovery World heard from attendees and experts, including ScaleReady's Josh Ludwig, about the obstacles the sector needs to overcome to succeed.
Read the article : Drug Discovery World: Challenges Facing Advanced TherapiesShare: Drug Discovery World: Challenges Facing Advanced Therapies
Scrip Citeline Commercial: What Does 2024 Hold For Biopharma?
Scrips Citeline Commercial
Josh Ludwig joins industry experts in discussing what 2024 has in store for the biopharma industry, including improvements for delivery of cell and gene therapies, a focus by contract manufacturers…
Read the article : Scrip Citeline Commercial: What Does 2024 Hold For Biopharma?Share: Scrip Citeline Commercial: What Does 2024 Hold For Biopharma?
APM Health: Automobile-like Production Model Can Cut CAR-T Costs and Ease Patient Access
APM Health
The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients.
Read the article : APM Health: Automobile-like Production Model Can Cut CAR-T Costs and Ease Patient AccessShare: APM Health: Automobile-like Production Model Can Cut CAR-T Costs and Ease Patient Access
The Medicine Maker: 2023 in Review – Interviews to Inspire
The Medicine Maker
The gears driving Industry 4.0 continue to catalyze many aspects of production in all industries. With pharma being traditionally known for lagging somewhat in this uptake, we gathered four experts to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing.
Read the article : The Medicine Maker: 2023 in Review – Interviews to InspireShare: The Medicine Maker: 2023 in Review – Interviews to Inspire
Pharma’s Almanac: Significant Regulatory Guidance on the Horizon for 2024
Pharma's Almanac
Pharma's Almanac asked industry experts, including ScaleReady's Global Director Josh Ludwig, their thoughts on the most significant regulatory decisions or guidance on the horizon for 2024. Josh discusses establishing more comprehensive and flexible guidelines for CGTs that will provide the clarity needed to enable creative, high-throughput manufacturing strategies.
Read the article : Pharma’s Almanac: Significant Regulatory Guidance on the Horizon for 2024Share: Pharma’s Almanac: Significant Regulatory Guidance on the Horizon for 2024
Pharma’s Almanac: Consequential Events in Biopharma in 2023
Pharma's Almanac
Josh Ludwig, Global Director of ScaleReady, joins Pharma's Almanac and biopharma industry experts to discuss the most consequential events and results of 2023. Josh reviews how investment setbacks have instigated a pivotal paradigm shift in cell therapy manufacturing this year.
Read the article : Pharma’s Almanac: Consequential Events in Biopharma in 2023Share: Pharma’s Almanac: Consequential Events in Biopharma in 2023
European Pharmaceutical Manufacturer: Simplifying Cell and Gene Therapy
European Pharmaceutical Manufacturer
Before investing in advanced tech, manufacturers must fully understand AI and automation in the unique context of CGT production. Josh Ludwig, Global Director, ScaleReady writes about the importance of simplifying existing CGT manufacturing processes before integrating AI and automation, ensuring a smooth transition.
Read the article : European Pharmaceutical Manufacturer: Simplifying Cell and Gene TherapyShare: European Pharmaceutical Manufacturer: Simplifying Cell and Gene Therapy
Genetic Engineering & Biotechnology News: Scaling Up the Cell Therapy Industry
Genetic Engineering & Biotechnology News
To meet rising patient demand, the cell and gene therapy industry must rapidly scale up production through advancements in automation, talent acquisition, and supply chain management. Genetic Engineering & Biotechnology News discusses advancements in cell therapy industry growth, including the ScaleReady joint venture.
Read the article : Genetic Engineering & Biotechnology News: Scaling Up the Cell Therapy IndustryShare: Genetic Engineering & Biotechnology News: Scaling Up the Cell Therapy Industry
